Mechanically Ventilated PatientsNCT05588180
The Ratio Of Femoral Vein Diameter To Femoral Artery Diameter With Pulse Pressure Variation As A Diagnostic Tool
A study testing FVD/FAD ratio guided and PPV in people with Mechanically Ventilated Patients, run by Fayoum University Hospital at 1 site in Egypt.
Trial summary
In assessing critically ill patients, an accurate assessment of a patient's volume status and whether they will respond to a fluid challenge with an increase in cardiac output is vital. 1 When hypovolemia is detected, volume expansion is utilized to enhance hemodynamics and restore normal blood pressure. Read more about this study
- Who is it for?
- Ages 18 to 60 years
- Conditions the study is for
- Mechanically Ventilated Patients
- What is being tested?
- FVD/FAD ratio guided and PPV
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteEgypt
- Study dates
- 18 Oct 2022to 20 May 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- patients on mechanical ventilation
Who cannot join
- cardiac arrhythmias
- previously known significant valvular disease or intracardiac shunt
- air leakage through chest drains
- increasing intraabdominal pressure
- norepinephrine infusion as it decreases PPV and SVV
- peripheral vascular diseases
- ARDS
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Comparing The Ratio Of Femoral Vein Diameter To Femoral Artery Diameter With Pulse Pressure Variation As A Diagnostic Tool For Fluid Responsiveness In Mechanically Ventilated Patients; A Prospective Observational Study
In assessing critically ill patients, an accurate assessment of a patient's volume status and whether they will respond to a fluid challenge with an increase in cardiac output is vital. 1 When hypovolemia is detected, volume expansion is utilized to enhance hemodynamics and restore normal blood pressure. 2 Hemodynamic tests (right atrial pressure, pulmonary artery occlusion pressure, and cardiac output ) are used to assess preload in critically ill patients, although these indexes are not necessarily reliable predictors of fluid status. According to the Starling law, fluid administration is hypothesized to boost cardiac output by raising preload, which describes a positive relationship between cardiac muscle fiber length and contractility. However, the Starling curve hits a plateau beyond its ascending leg, and additional fluid administration can be hazardous, leading to right ventricular overload and pulmonary edema Invasive or noninvasive techniques can be used to determine blood volume status. Assessments such as central venous pressure (CVP) and mean pulmonary artery pressure (mPAP) are both invasive procedures. Various factors influence CVP (including thoracic, pericardial, abdominal pressures, etc.). CVP can be used as a fluid management indication, although It can be misused to estimate blood volume or mislead methods for treatment. Dynamic indices such as stroke volume variation (SVV) and pulse pressure variation (PPV) are superior to static indices for assessing volume status. However, these dynamic indices are unreliable when a patient is ventilated with low tidal volume, such as acute respiratory distress syndrome (ARDS); the tidal volume is insufficient to change intrathoracic pressure significantly. Ultrasound (US) evaluation of the inferior vena cava (IVC) may help determine fluid status.
Read the detailed description
The study will be conducted in intensive care units of Fayoum University Hospitals after approval of the local institutional ethics committee, and the local institutional review board will approve the study. The inclusion criteria will be as follows: patients on mechanical ventilation(MV), aged between 18 and 60 years with circulatory failure defined as mean arterial pressure (MAP) less than 65 mmHg or systolic arterial pressure less than 90mm Hg with signs of hypoperfusion (urinary flow < 0.5mL/kg/ min for > 2hr, tachycardia > 100 beats/min, or presence of skin mottling, and serum lactate more than 2 mmol/L) 17 and showing positive PLRT. The exclusion criteria: cardiac arrhythmias, previously known significant valvular disease or intracardiac shunt, air leakage through chest drains, increasing intraabdominal pressure, norepinephrine infusion as it decreases PPV and SVV, masking their ability for the detection of FR15
, peripheral vascular diseases, ARDS patients due to low tidal volume a, Contraindication for fluid administration as cardiogenic shock, acute pulmonary edema or LVEF% less than 50%. , renal patients with oliguria and volume overload including patients on hemodialysis or patients with acute anuric renal failure., patients with lower extremity artery/vein thrombosis, significant lower extremity artery plaque, lower extremity artery occlusion, inferior vena cava filter implantation, lower extremity varicose veins,
All patients fulfilling criteria will be monitored by (1) 6 leads ECG, (2) noninvasive BP, (3)urinary catheter for UOP, (4) pulse oximeter then divided into 2 groups, group (P) PPV guided group and group (F) FVD/FAD ratio guided
Randomization of patients to each of the treatment groups will be done by a statistician not involved in the study, using the website randomization.com. The allocation concealment will be done by contacting the statistician giving him the patient number, age, and sex to receive the patient allocation in a sealed envelop.
The envelope is to be received and opened after the informed consent is obtained Neither the participants, the study investigator, the attending clinicians, nor the data collector will be aware of groups allocation till the study end. The Consolidated Standards of Reporting Trials (CONSORT)recommendation will be followed. Group (P):(n=30), patients will be temporarily sedated and paralyzed and on fully controlled mechanical ventilation. No spontaneous breathing effort will be detected on the mechanical ventilator waveform monitor, ensuring that the respiratory changes in arterial pressure reflect only the effects of positive pressure ventilation. Modes of ventilation are selected to volume or pressure-controlled ventilation, depending on the decision of the primary physicians. A tidal volume will be set to not less than 8 ml/ kg (predicted body weight). The preset respiratory rate will be set at 14 breaths/min. Positive end-expiratory pressure (PEEP) will be between 8 and 10 cmH2O. The plateau pressure was kept at below 30 cmH2O. In all patients, radial artery cannulation will be done for invasive blood pressure monitoring (using a 20 G cannula), PPV is calculated directly on Nihon Kohden monitors at the base line then infusion of 4ml/kg /h of crystalloids will be infused till PPV will be less than 13%. 15
Group(F) : (n=30), FVD/FAD ratio guided; US probe will be used first to find the bifurcation position of the femoral artery, and then the probe will be retracted proximally. The visual field of the bifurcation will disappear until the probe enters the main branch of the femoral artery, and the femoral artery and vein could be observed simultaneously. Under normal conditions, pulsation indicates the femoral artery, and its companion is the femoral vein. The mean FVD and FAD will be measured then the FVD / FAD ratio will be calculated.
- Conditions
- Mechanically Ventilated Patients
- Being tested
- FVD/FAD ratio guided, PPV
- Keywords
- mechanically ventilated patients, FVD / FAD
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
FVD/FAD ratio guidedProcedure or surgery
Ultrasound-guided ratio
PPVProcedure or surgery
PPV
| Study group | Role | What they receive |
|---|---|---|
| Group (P) | Active comparator | Group (P) PPV guided group Receives: Procedure: PPV |
| Group (F) | Active comparator | Group (F) FVD/FAD ratio guided Receives: Procedure: FVD/FAD ratio guided |
What is being measured
The primary outcome is the main question the study is designed to answer.
MAP
mean arterial blood pressure
Measured: the first 48 hours postoperative
Secondary outcomes (2)
the cutoff value of FVD/FAD reflecting FR
the cutoff value of FVD/FAD reflecting FR
Measured: the first 48 hours postoperative
PPV
pulse variation index
Measured: the first 48 hours postoperative
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Oct 2022
- Study start18 Oct 2022
- Primary completion15 May 2023
- Study completion20 May 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Mechanically Ventilated PatientsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- group (F) FVD/FAD ratio guided
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- Fayoum University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mohamed Ahmed Hamed, Fayoum University Hospital
- Investigators
- Mohamed Hamed, M D, Principal investigator, Fayoum University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05588180
- Sponsor's protocol ID
- M 600
- Status last verified
- May 2023
- First submitted
- 18 Oct 2022
- Last updated
- 24 May 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: No plan to share data
Publications
Kalantari K, Chang JN, Ronco C, Rosner MH. Assessment of intravascular volume status and volume responsiveness in critically ill patients. Kidney Int. 2013 Jun;83(6):1017-28. doi: 10.1038/ki.2012.424. Epub 2013 Jan 9.
PubMed 23302716Monnet X, Marik PE, Teboul JL. Prediction of fluid responsiveness: an update. Ann Intensive Care. 2016 Dec;6(1):111. doi: 10.1186/s13613-016-0216-7. Epub 2016 Nov 17.
PubMed 27858374
Study at a glance
From the registry record, last updated by the sponsor on 24 May 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparing The Ratio Of Femoral Vein Diameter To Femoral Artery Diameter With Pulse Pressure Variation As A Diagnostic Tool For Fluid Responsiveness In Mechanically Ventilated Patients; A Prospective Observational Study
- ClinicalTrials.gov ID
- NCT05588180
- Acronym / sponsor ID
- M 600
- Conditions
- Mechanically Ventilated Patients
- Keywords
- mechanically ventilated patients, FVD / FAD
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 60 participants (actual)
- Lead sponsor
- Fayoum University HospitalUniversity, hospital or other
- Study start
- 18 Oct 2022 (actual)
- Primary completion
- 15 May 2023 (actual)
- Study completion
- 20 May 2023 (actual)
- First posted
- 20 Oct 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In assessing critically ill patients, an accurate assessment of a patient's volume status and whether they will respond to a fluid challenge with an increase in cardiac output is vital. 1 When hypovolemia is detected, volume expansion is utilized to enhance hemodynamics and restore normal blood pressure. 2 Hemodynamic tests (right atrial pressure, pulmonary artery occlusion pressure, and cardiac output ) are used to assess preload in critically ill patients, although these indexes are not necessarily reliable predictors of fluid status. According to the Starling law, fluid administration is hypothesized to boost cardiac output by raising preload, which describes a positive relationship between cardiac muscle fiber length and contractility. However, the Starling curve hits a plateau beyond its ascending leg, and additional fluid administration can be hazardous, leading to right ventricular overload and pulmonary edema Invasive or noninvasive techniques can be used to determine blood volume status. Assessments such as central venous pressure (CVP) and mean pulmonary artery pressure (mPAP) are both invasive procedures. Various factors influence CVP (including thoracic, pericardial, abdominal pressures, etc.). CVP can be used as a fluid management indication, although It can be misused to estimate blood volume or mislead methods for treatment. Dynamic indices such as stroke volume variation (SVV) and pulse pressure variation (PPV) are superior to static indices for assessing volume status. However, these dynamic indices are unreliable when a patient is ventilated with low tidal volume, such as acute respiratory distress syndrome (ARDS); the tidal volume is insufficient to change intrathoracic pressure significantly. Ultrasound (US) evaluation of the inferior vena cava (IVC) may help determine fluid status.
Detailed description
The study will be conducted in intensive care units of Fayoum University Hospitals after approval of the local institutional ethics committee, and the local institutional review board will approve the study. The inclusion criteria will be as follows: patients on mechanical ventilation(MV), aged between 18 and 60 years with circulatory failure defined as mean arterial pressure (MAP) less than 65 mmHg or systolic arterial pressure less than 90mm Hg with signs of hypoperfusion (urinary flow < 0.5mL/kg/ min for > 2hr, tachycardia > 100 beats/min, or presence of skin mottling, and serum lactate more than 2 mmol/L) 17 and showing positive PLRT. The exclusion criteria: cardiac arrhythmias, previously known significant valvular disease or intracardiac shunt, air leakage through chest drains, increasing intraabdominal pressure, norepinephrine infusion as it decreases PPV and SVV, masking their ability for the detection of FR15
, peripheral vascular diseases, ARDS patients due to low tidal volume a, Contraindication for fluid administration as cardiogenic shock, acute pulmonary edema or LVEF% less than 50%. , renal patients with oliguria and volume overload including patients on hemodialysis or patients with acute anuric renal failure., patients with lower extremity artery/vein thrombosis, significant lower extremity artery plaque, lower extremity artery occlusion, inferior vena cava filter implantation, lower extremity varicose veins,
All patients fulfilling criteria will be monitored by (1) 6 leads ECG, (2) noninvasive BP, (3)urinary catheter for UOP, (4) pulse oximeter then divided into 2 groups, group (P) PPV guided group and group (F) FVD/FAD ratio guided
Randomization of patients to each of the treatment groups will be done by a statistician not involved in the study, using the website randomization.com. The allocation concealment will be done by contacting the statistician giving him the patient number, age, and sex to receive the patient allocation in a sealed envelop.
The envelope is to be received and opened after the informed consent is obtained Neither the participants, the study investigator, the attending clinicians, nor the data collector will be aware of groups allocation till the study end. The Consolidated Standards of Reporting Trials (CONSORT)recommendation will be followed. Group (P):(n=30), patients will be temporarily sedated and paralyzed and on fully controlled mechanical ventilation. No spontaneous breathing effort will be detected on the mechanical ventilator waveform monitor, ensuring that the respiratory changes in arterial pressure reflect only the effects of positive pressure ventilation. Modes of ventilation are selected to volume or pressure-controlled ventilation, depending on the decision of the primary physicians. A tidal volume will be set to not less than 8 ml/ kg (predicted body weight). The preset respiratory rate will be set at 14 breaths/min. Positive end-expiratory pressure (PEEP) will be between 8 and 10 cmH2O. The plateau pressure was kept at below 30 cmH2O. In all patients, radial artery cannulation will be done for invasive blood pressure monitoring (using a 20 G cannula), PPV is calculated directly on Nihon Kohden monitors at the base line then infusion of 4ml/kg /h of crystalloids will be infused till PPV will be less than 13%. 15
Group(F) : (n=30), FVD/FAD ratio guided; US probe will be used first to find the bifurcation position of the femoral artery, and then the probe will be retracted proximally. The visual field of the bifurcation will disappear until the probe enters the main branch of the femoral artery, and the femoral artery and vein could be observed simultaneously. Under normal conditions, pulsation indicates the femoral artery, and its companion is the femoral vein. The mean FVD and FAD will be measured then the FVD / FAD ratio will be calculated.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- group (F) FVD/FAD ratio guided
| Arm | Type | Receives |
|---|---|---|
| Group (P) | Active comparator | Procedure: PPVGroup (P) PPV guided group |
| Group (F) | Active comparator | Procedure: FVD/FAD ratio guidedGroup (F) FVD/FAD ratio guided |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- patients on mechanical ventilation
Key exclusion criteria (7 listed)
- cardiac arrhythmias
- previously known significant valvular disease or intracardiac shunt
- air leakage through chest drains
- increasing intraabdominal pressure
- norepinephrine infusion as it decreases PPV and SVV
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| FVD/FAD ratio guidedUltrasound-guided ratio | Procedure or surgery | Group (F) |
| PPVPPV | Procedure or surgery | Group (P) |
Primary outcome
MAP
Time frame: the first 48 hours postoperative
mean arterial blood pressure
2 secondary outcomes
the cutoff value of FVD/FAD reflecting FR
Time frame: the first 48 hours postoperative
PPV
Time frame: the first 48 hours postoperative
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 May 2023.
- Results publication: PubMed 23302716Kalantari K, Chang JN, Ronco C, Rosner MH. Assessment of intravascular volume status and volume responsiveness in critically ill patients. Kidney Int. 2013 Jun;83(6):1017-28. doi: 10.1038/ki.2012.424. Epub 2013 Jan 9.
- Results publication: PubMed 27858374Monnet X, Marik PE, Teboul JL. Prediction of fluid responsiveness: an update. Ann Intensive Care. 2016 Dec;6(1):111. doi: 10.1186/s13613-016-0216-7. Epub 2016 Nov 17.
- Individual participant dataSharing planned: No. No plan to share data
Related trials for Mechanically Ventilated Patients
Not yet recruiting
Mechanical Ventilator Adjustments and Patient Dyspnea
Respiratory Failure, Dyspnea During Mechanical Ventilation
RecruitingObservational study
Predicting Extubation Failure Using Machine Learning
Extubation Failure, Critical Illness
RecruitingObservational study
Comparison of PPV and LVOT VTI During Passive Leg Raising to Predict Fluid Responsiveness
Hemodynamic Instability, Hypovolemia
RecruitingObservational study
Role of End-Tidal CO2 During Passive Leg Raising to Predict Fluid Responsiveness in ICU
Circulatory Failure, Critical Illness
Recruiting
Blood Flow Restriction Training for Mechanically Ventilated Patients With ICU-Acquired Weakness
Intensive Care Unit Acquired Weakness
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mohamed Hamed, M D principal investigator
Fayoum University Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing FVD/FAD ratio guided and PPV in people with Mechanically Ventilated Patients, run by Fayoum University Hospital at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 May 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
MAP (time frame: the first 48 hours postoperative). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05588180, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 May 2023.